2022: the Year in Cardiovascular Disease - the Year of Upfront Lipid Lowering Combination Therapy

Overview

Journal Arch Med Sci

Specialty General Medicine

Date 2022 Dec 2

PMID 36457968

Authors

Maciej Banach

Zeljko Reiner

Arrigo F G Cicero

Pierre Sabouret

Margus Viigimaa

Amirhossein Sahebkar

Arman Postadzhiyan

Dan Gaita

Daniel Pella

Peter E Penson

Affiliations

Soon will be listed here.

Citing Articles

2024 consensus document of the Italian Society of Arterial Hypertension (SIIA) and the Italian Society of Cardiovascular Prevention (SIPREC): update on LDL cholesterol lowering in patients with arterial hypertension.

Muiesan M, Virdis A, Tocci G, Borghi C, Cicero A, Ferri C High Blood Press Cardiovasc Prev. 2025; 32(2):151-163.

PMID: 39998741 DOI: 10.1007/s40292-024-00700-x.

Impact of surrogates for insulin resistance on mortality and life expectancy in primary care: a nationwide cross-sectional study with registry linkage (LIPIDOGRAM2015).

Chen Y, Zhong Z, Gue Y, Banach M, McDowell G, Mikhailidis D Lancet Reg Health Eur. 2025; 49:101182.

PMID: 39759579 PMC: 11697418. DOI: 10.1016/j.lanepe.2024.101182.

Looking Back, Leaning Forward-A Contemporary Overview of Acute Coronary Syndrome.

Fardman A, Chernomordik F, Beigel R J Clin Med. 2024; 13(23).

PMID: 39685794 PMC: 11642022. DOI: 10.3390/jcm13237331.

Lipoprotein(a) and other risk factors in dyslipidemic patients with and without heart failure.

Lewek J, Sosnowska B, Bielecka-Dabrowa A, Mierczak K, Adach W, Banach M Arch Med Sci. 2024; 20(5):1705-1709.

PMID: 39649260 PMC: 11623177. DOI: 10.5114/aoms/194684.

Risk of adverse cardiovascular events based on common genetic variants in 8-year follow-up of the LIPIDOGEN2015 population using the polygenic risk score (PRS): study design and methodology.

Banach M, Fronczek M, Osadnik T, Gach A, Strapagiel D, Slomka M Arch Med Sci. 2024; 20(5):1452-1460.

PMID: 39649254 PMC: 11623186. DOI: 10.5114/aoms/192147.

References

Lyall D, Ward J, Banach M, Davey Smith G, Gill J, Pell J . genetic variants and cognitive abilities: a large-scale Mendelian randomization study. Arch Med Sci. 2021; 17(1):241-244. PMC: 7811317. DOI: 10.5114/aoms/127226. View

Banach M . Statin intolerance: time to stop letting it get in the way of treating patients. Lancet. 2022; 400(10355):791-793. DOI: 10.1016/S0140-6736(22)01643-9. View

Ray K, Molemans B, Schoonen W, Giovas P, Bray S, Kiru G . EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol. 2021; 28(11):1279-1289. DOI: 10.1093/eurjpc/zwaa047. View

Banach M, Shekoohi N, Mikhailidis D, Lip G, Hernandez A, Mazidi M . Relationship between low-density lipoprotein cholesterol, lipid-lowering agents and risk of stroke: a meta-analysis of observational studies ( = 355,591) and randomized controlled trials ( = 165,988). Arch Med Sci. 2022; 18(4):912-929. PMC: 9266957. DOI: 10.5114/aoms/145970. View

Banach M, Stulc T, Dent R, Toth P . Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. Int J Cardiol. 2016; 225:184-196. DOI: 10.1016/j.ijcard.2016.09.075. View

Banach M, Kazmierczak J, Mitkowski P, Wita K, Broncel M, Gasior M . Which patients at risk of cardiovascular disease might benefit the most from inclisiran? Polish experts' opinion. The compromise between EBM and possibilities in healthcare. Arch Med Sci. 2022; 18(3):569-576. PMC: 9103399. DOI: 10.5114/aoms/147435. View

Banach M, Penson P . Lipid-lowering therapies: Better together. Atherosclerosis. 2021; 320:86-88. DOI: 10.1016/j.atherosclerosis.2021.01.009. View

Cannon C, Khan I, Klimchak A, Reynolds M, Sanchez R, Sasiela W . Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2017; 2(9):959-966. PMC: 5710173. DOI: 10.1001/jamacardio.2017.2289. View

Banach M, Cannon C, Paneni F, Penson P . Individualized therapy in statin intolerance: the key to success. Eur Heart J. 2022; 44(7):544-546. DOI: 10.1093/eurheartj/ehac556. View

10.

Lewek J, Niedziela J, Desperak P, Dyrbus K, Osadnik T, Jankowski P . Intensive Statin Therapy Versus Upfront Combination Therapy of Statin and Ezetimibe in Patients With Acute Coronary Syndrome: A Propensity Score Matching Analysis Based on the PL-ACS Data. J Am Heart Assoc. 2023; 12(18):e030414. PMC: 10547305. DOI: 10.1161/JAHA.123.030414. View

11.

Penson P, Pirro M, Banach M . LDL-C: lower is better for longer-even at low risk. BMC Med. 2020; 18(1):320. PMC: 7545575. DOI: 10.1186/s12916-020-01792-7. View

12.

Shakour N, Ruscica M, Hadizadeh F, Cirtori C, Banach M, Jamialahmadi T . Statins and C-reactive protein: in silico evidence on direct interaction. Arch Med Sci. 2020; 16(6):1432-1439. PMC: 7667423. DOI: 10.5114/aoms.2020.100304. View

13.

Zandecki L, Janion M, Sadowski M, Kurzawski J, Polonski L, Gierlotka M . Associations of changes in patient characteristics and management with decrease in mortality rates of men and women with ST-elevation myocardial infarction - a propensity score-matched analysis. Arch Med Sci. 2020; 16(4):772-780. PMC: 7286320. DOI: 10.5114/aoms.2020.93458. View

14.

Vicente-Valor J, Garcia-Gonzalez X, Ibanez-Garcia S, Duran-Garcia M, de Lorenzo-Pinto A, Rodriguez-Gonzalez C . PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort. Biomed Pharmacother. 2021; 146:112519. DOI: 10.1016/j.biopha.2021.112519. View

15.

Banach M, Burchardt P, Chlebus K, Dobrowolski P, Dudek D, Dyrbus K . PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci. 2021; 17(6):1447-1547. PMC: 8641518. DOI: 10.5114/aoms/141941. View

16.

Bytyci I, Penson P, Mikhailidis D, Wong N, Hernandez A, Sahebkar A . Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022; 43(34):3213-3223. PMC: 9757867. DOI: 10.1093/eurheartj/ehac015. View

17.

Dyrbus K, Gasior M, Desperak P, Nowak J, Osadnik T, Banach M . Characteristics of lipid profile and effectiveness of management of dyslipidaemia in patients with acute coronary syndromes - Data from the TERCET registry with 19,287 patients. Pharmacol Res. 2018; 139:460-466. DOI: 10.1016/j.phrs.2018.12.002. View

18.

Lewek J, Konopka A, Starostecka E, Penson P, Maciejewski M, Banach M . Clinical Features of Familial Hypercholesterolemia in Children and Adults in EAS-FHSC Regional Center for Rare Diseases in Poland. J Clin Med. 2021; 10(19). PMC: 8509252. DOI: 10.3390/jcm10194302. View

19.

Cannon C, de Lemos J, Rosenson R, Ballantyne C, Liu Y, Gao Q . Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US. JAMA Cardiol. 2021; 6(9):1060-1068. PMC: 8209562. DOI: 10.1001/jamacardio.2021.1810. View

20.

Nowowiejska-Wiewiora A, Wita K, Medrala Z, Tomkiewicz-Pajak L, Bujak K, Mizia-Stec K . Dyslipidemia treatment and attainment of LDL-cholesterol treatment goals in patients participating in the Managed Care for Acute Myocardial Infarction Survivors program. Kardiol Pol. 2023; 81(4):359-365. DOI: 10.33963/KP.a2023.0045. View